Bank Of New York Mellon Corp Gemini Therapeutics, Inc. Transaction History

Bank Of New York Mellon Corp

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$1.22 - $1.73 $70,845 - $100,461	-58,070 Reduced 84.06%	11,008 $19,000
Q1 2022 May 11, 2022	SELL	$1.29 - $3.08 $2,140 - $5,109	-1,659 Reduced 2.35%	69,078 $96,000
Q4 2021 Feb 11, 2022	SELL	$2.39 - $4.0 $5,549 - $9,288	-2,322 Reduced 3.18%	70,737 $205,000
Q3 2021 Nov 12, 2021	BUY	$3.3 - $6.32 $34,663 - $66,385	10,504 Added 16.79%	73,059 $295,000
Q2 2021 Aug 11, 2021	BUY	$6.32 - $14.02 $321,713 - $713,674	50,904 Added 436.91%	62,555 $404,000
Q1 2021 May 13, 2021	BUY	$11.32 - $18.0 $131,889 - $209,718	11,651 New	11,651 $157,000

2.44M

Ticker GMTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,244,500
Market Cap $1.05B
Description
Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 ...

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

Stay updated on Bank Of New York Mellon Corp with notifications on news.